Is Lymphocyte C-Reactive Protein Ratio Useful for Predicting Survival in Patients with Non-Metastatic Soft Tissue Sarcoma?
- PMID: 36358634
- PMCID: PMC9655955
- DOI: 10.3390/cancers14215214
Is Lymphocyte C-Reactive Protein Ratio Useful for Predicting Survival in Patients with Non-Metastatic Soft Tissue Sarcoma?
Abstract
Background: Recently, the lymphocyte-to-CRP ratio (LCR) was found to have a prognostic role in many cancers. However, the clinical significance of LCR in patients with soft tissue sarcoma (STS) has not yet been established. This study aimed to determine whether LCR can predict disease-specific survival (DSS) and event-free survival (EFS) in patients with STS. Methods: In this study, 132 patients were enrolled. The mean follow-up periods were 76.5 months. Blood examinations were performed prior to treatment for all patients. Results: The 5-year DSS in patients with higher and lower LCR was 86.5% and 52.8%, respectively (p < 0.001). Patients with lower LCR had worse survival than those with higher LCR. The 5-year EFS in patients with higher and lower LCR was 66.2% and 31.2%, respectively (p < 0.001). On Receiver operating characteristic analysis, however, there was no significant difference in the area under curve (AUC) between CRP level (AUC = 0.72) and LCR (AUC = 0.711). Conclusions: LCR may be a prognostic factor for predicting oncological events in multivariate analysis, although ROC analysis could not show the superiority of LCR to CRP for predicting oncological outcomes in patients with STS.
Keywords: lymphocyte- to- C-reactive protein ratio; soft tissue sarcoma; survival.
Conflict of interest statement
The authors declare no conflict of interest.
Figures




Similar articles
-
Comparison of Lymphocyte-CRP Ratio to Conventional Inflammatory Markers for Predicting Clinical Outcomes in COVID-19.J Pers Med. 2023 May 29;13(6):909. doi: 10.3390/jpm13060909. J Pers Med. 2023. PMID: 37373898 Free PMC article.
-
Clinical utility of lymphocyte to C-reactive protein ratio in predicting survival and postoperative complication for esophago-gastric junction cancer.Surg Oncol. 2022 Sep;44:101842. doi: 10.1016/j.suronc.2022.101842. Epub 2022 Aug 30. Surg Oncol. 2022. PMID: 36081281
-
Prognostic Significance of Preoperative Lymphocyte-to-C-Reactive Protein Ratio in Patients with Non-Metastatic Colorectal Cancer.Onco Targets Ther. 2021 Jan 12;14:337-346. doi: 10.2147/OTT.S290234. eCollection 2021. Onco Targets Ther. 2021. PMID: 33469310 Free PMC article.
-
Meta-Analysis of Hematological Biomarkers as Reliable Indicators of Soft Tissue Sarcoma Prognosis.Front Oncol. 2020 Jan 30;10:30. doi: 10.3389/fonc.2020.00030. eCollection 2020. Front Oncol. 2020. PMID: 32082998 Free PMC article.
-
The value of C-reactive protein as an independent prognostic indicator for disease-specific survival in patients with soft tissue sarcoma: A meta-analysis.PLoS One. 2019 Jul 1;14(7):e0219215. doi: 10.1371/journal.pone.0219215. eCollection 2019. PLoS One. 2019. PMID: 31260491 Free PMC article.
Cited by
-
C‑reactive protein and related predictors in soft tissue sarcoma (Review).Mol Clin Oncol. 2023 Nov 24;20(1):6. doi: 10.3892/mco.2023.2704. eCollection 2024 Jan. Mol Clin Oncol. 2023. PMID: 38125741 Free PMC article. Review.
-
The Combined Use of Inflammation Markers, Modified Glasgow Prognostic Score, and Sarculator Nomogram in Extremity Soft Tissue Sarcoma: A Multicenter Observational Study.Cancers (Basel). 2024 Mar 6;16(5):1077. doi: 10.3390/cancers16051077. Cancers (Basel). 2024. PMID: 38473433 Free PMC article.
-
Comprehensive comparative analysis of the prognostic impact of systemic inflammation biomarkers for patients underwent cardiac surgery.Front Immunol. 2023 Aug 14;14:1190380. doi: 10.3389/fimmu.2023.1190380. eCollection 2023. Front Immunol. 2023. PMID: 37646036 Free PMC article.
References
-
- Nakamura T., Asanuma K., Takao M., Yamanaka T., Koike H., Chen-Yoshikawa T.F., Tsukushi S., Kuroda H., Kozawa E., Sano M., et al. Clinical Outcome in Soft Tissue Sarcoma Patients with Lung Metastasis Who Received Metastasectomy and/or Radiofrequency Ablation: Tokai Musculoskeletal Oncology Consortium Study. Cancer Manag. Res. 2021;13:8473–8480. doi: 10.2147/CMAR.S333721. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous